Issue Date: August 18, 2008
UCB Transfers England R&D To BioFocus
Belgian pharmaceuticals company UCB has shifted its England-based medicinal chemistry operation to Galapagos’ services subsidiary, BioFocus DPI. The value of the contract for BioFocus could exceed $6 million. Additionally, BioFocus is eligible to receive up to $750,000 in milestone payments. UCB will transfer a team of chemists from its recently closed Cambridge, England, research site to BioFocus, which will continue chemistry work on a UCB drug program until a candidate is selected. Under the contract, UCB will provide biology support for the program.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society